This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

ARS Pharmaceuticals files US antitrust claims against AptarGroup over emergency nasal sprays

( September 29, 2025, 22:31 GMT | Official Statement) -- MLex Summary: ARS Pharmaceuticals Operations filed a US complaint accusing AptarGroup of illegally limiting competition to its emergency-use single-dose intranasal spray system through exclusionary policies to delay competitive entry and thereby extend its ability to overcharge for inputs. “As a result of Aptar’s exclusionary new policies, ARS is left with no choice but to purchase both rubber plungers and single-dose intranasal systems from Aptar at close to parity volumes, rather than shifting additional demand to the new entrant, Silgan,” it said. See attached file....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections